Nanaomycin A 

Nanaomycin A is the first selective DNMT3B inhibitor with an IC₅₀ of 500 nM. Nanaomycin A, a quinone antibiotics, reactivates silenced tumor suppressor genes in human cancer cells^[1]. Nanaomycin A inhibits in vitro growth of the human malaria parasite Plasmodium falciparum with an IC₈₀ value of 33.1 nM^[2].

Nanaomycin A (10-10000 nM; 72 hours) has a distinct cytotoxic effect in all three cell lines^[1].
Nanaomycin A (0.5, 5 μM; 72 hours) reveals induction of RASSF1A protein expression in A549 cells^[1].
Nanaomycin A (5 μM; 72 hours) has an 18-fold relative induction^[1].
Nanaomycin A not affects the enzymatic activity of DNMT1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

302.28

C₁₆H₁₄O₆

52934-83-5

Solid

Yellow to orange

O=C(O)C[C@H]1CC(C(C2=C3C(O)=CC=C2)=O)=C(C3=O)[C@H](C)O1

Room temperature in continental US; may vary elsewhere.

• [1]. Kuck D, et al.Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells.Mol Cancer Ther. 2010 Nov;9(11):3015-23.  [Content Brief]

  [2]. Tanaka Y, et al.Heme-dependent radical generation: possible involvement in antimalarial action of non-peroxide microbial metabolites, nanaomycin A and radicicol.J Antibiot (Tokyo). 1999 Oct;52(10):880-8.  [Content Brief]